Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS.NS)
INR 56.84
(0.0%)
INR 56.84
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 45.16 Million INR | -57.43% |
| 2022 | 82.65 Million INR | -25.05% |
| 2021 | 120.14 Million INR | 20.83% |
| 2020 | 91.5 Million INR | 17.35% |
| 2019 | 72.47 Million INR | -18.93% |
| 2018 | 101.37 Million INR | 13.0% |
| 2017 | 82.39 Million INR | 5.18% |
| 2016 | 98.18 Million INR | 152.1% |
| 2015 | 12.14 Million INR | 9.65% |
| 2014 | 15.07 Million INR | 146.32% |
| 2013 | 15.46 Million INR | -31.0% |
| 2012 | 21.73 Million INR | 27.11% |
| 2011 | 17.05 Million INR | 5.07% |
| 2010 | 15.98 Million INR | 14.65% |
| 2009 | 14.19 Million INR | -13.92% |
| 2008 | 14.01 Million INR | 40.3% |
| 2007 | 11.75 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 11.78 Million INR | -25.6% |
| 2023 FY | - INR | -57.43% |
| 2023 Q1 | 20.35 Million INR | -39.47% |
| 2023 Q3 | 27.03 Million INR | 0.75% |
| 2023 Q2 | 26.83 Million INR | 31.8% |
| 2023 Q4 | -14.38 Million INR | -153.2% |
| 2022 FY | - INR | -25.05% |
| 2022 Q4 | 33.63 Million INR | 67.57% |
| 2022 Q1 | 17.54 Million INR | -39.67% |
| 2022 Q2 | 33.31 Million INR | 89.89% |
| 2022 Q3 | 20.07 Million INR | -39.75% |
| 2021 Q2 | 42.32 Million INR | 17.59% |
| 2021 Q1 | 35.99 Million INR | -7.53% |
| 2021 Q3 | 31.88 Million INR | -24.68% |
| 2021 Q4 | 29.07 Million INR | -8.8% |
| 2021 FY | - INR | 20.83% |
| 2020 FY | - INR | 17.35% |
| 2020 Q1 | 22.48 Million INR | -21.27% |
| 2020 Q4 | 38.92 Million INR | 53.51% |
| 2020 Q3 | 25.35 Million INR | -11.65% |
| 2020 Q2 | 28.69 Million INR | 27.64% |
| 2019 Q3 | 21.61 Million INR | 6.32% |
| 2019 Q4 | 28.55 Million INR | 32.13% |
| 2019 Q1 | 27.72 Million INR | -34.14% |
| 2019 FY | - INR | -18.93% |
| 2019 Q2 | 20.32 Million INR | -26.69% |
| 2018 Q2 | 27.57 Million INR | 12.75% |
| 2018 Q1 | 24.46 Million INR | -33.17% |
| 2018 Q3 | 27.2 Million INR | -1.34% |
| 2018 FY | - INR | 13.0% |
| 2018 Q4 | 42.1 Million INR | 54.75% |
| 2017 FY | - INR | 5.18% |
| 2017 Q4 | 36.59 Million INR | 41.64% |
| 2017 Q3 | 25.83 Million INR | 21.8% |
| 2017 Q2 | 21.21 Million INR | -12.24% |
| 2017 Q1 | 24.17 Million INR | -45.49% |
| 2016 Q2 | 28.96 Million INR | 9.0% |
| 2016 Q3 | 33.13 Million INR | 14.41% |
| 2016 FY | - INR | 152.1% |
| 2016 Q4 | 44.35 Million INR | 33.84% |
| 2016 Q1 | 26.57 Million INR | 168.7% |
| 2015 Q4 | 9.89 Million INR | 19.65% |
| 2015 FY | - INR | 9.65% |
| 2015 Q3 | 8.26 Million INR | -22.91% |
| 2015 Q2 | 10.72 Million INR | -8.57% |
| 2015 Q1 | 11.72 Million INR | -17.29% |
| 2014 Q4 | 14.17 Million INR | 111.04% |
| 2014 FY | - INR | 146.32% |
| 2014 Q1 | 9.96 Million INR | 204.66% |
| 2014 Q2 | 6.07 Million INR | -39.04% |
| 2014 Q3 | 6.71 Million INR | 10.6% |
| 2013 Q4 | -9.52 Million INR | -259.99% |
| 2013 FY | - INR | -31.0% |
| 2013 Q1 | 5.68 Million INR | 55.1% |
| 2013 Q2 | 12.87 Million INR | 126.37% |
| 2013 Q3 | 5.95 Million INR | -53.78% |
| 2012 Q3 | 6.19 Million INR | -23.19% |
| 2012 Q1 | 7.03 Million INR | 945.71% |
| 2012 FY | - INR | 27.11% |
| 2012 Q2 | 8.06 Million INR | 14.52% |
| 2012 Q4 | 3.66 Million INR | -40.75% |
| 2011 Q3 | 5.99 Million INR | 0.0% |
| 2011 Q4 | -832.2 Thousand INR | -113.88% |
| 2011 FY | - INR | 5.07% |
| 2010 FY | - INR | 14.65% |
| 2009 FY | - INR | -13.92% |
| 2008 Q4 | 6.03 Million INR | 0.0% |
| 2008 FY | - INR | 40.3% |
| 2007 FY | - INR | 0.0% |
| 2007 Q4 | 5.29 Million INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | 94.887% |
| Ind-Swift Limited | 1.06 Billion INR | 95.759% |
| Bajaj HealthCare Limited | 406.23 Million INR | 88.882% |
| Sakar Healthcare Limited | 393.26 Million INR | 88.515% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.927% |
| Innova Captab Limited | 1.66 Billion INR | 97.293% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.822% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 98.084% |
| Morepen Laboratories Limited | 1.72 Billion INR | 97.383% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.839% |
| Sequent Scientific Limited | 549.8 Million INR | 91.785% |
| Wanbury Limited | 985.49 Million INR | 95.417% |
| Laurus Labs Limited | 8 Billion INR | 99.436% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 97.059% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 99.342% |
| Alembic Limited | 1.11 Billion INR | 95.954% |
| Hikal Limited | 2.69 Billion INR | 98.322% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 99.53% |
| Neuland Laboratories Limited | 4.74 Billion INR | 99.049% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 99.516% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 99.602% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 98.267% |
| Themis Medicare Limited | 562.6 Million INR | 91.972% |
| RPG Life Sciences Limited | 1.28 Billion INR | 96.476% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.92% |
| Lupin Limited | 36.96 Billion INR | 99.878% |
| Amrutanjan Health Care Limited | 681.59 Million INR | 93.374% |
| Wockhardt Limited | 1.08 Billion INR | 95.818% |
| Vaishali Pharma Limited | 31.71 Million INR | -42.427% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 98.845% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 86.037% |
| Jubilant Pharmova Limited | 8 Billion INR | 99.436% |
| FDC Limited | 3.38 Billion INR | 98.666% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.949% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 84.286% |
| Eris Lifesciences Limited | 6.98 Billion INR | 99.354% |
| Venus Remedies Limited | 711.8 Million INR | 93.655% |
| ZIM Laboratories Limited | 462.09 Million INR | 90.226% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 96.946% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | 80.206% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 99.27% |
| Shilpa Medicare Limited | 2.58 Billion INR | 98.255% |
| Albert David Limited | 1.04 Billion INR | 95.68% |
| Ajanta Pharma Limited | 12.56 Billion INR | 99.641% |
| Hester Biosciences Limited | 539.47 Million INR | 91.628% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 99.034% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 101.601% |
| Gufic Biosciences Limited | 1.48 Billion INR | 96.949% |
| Windlas Biotech Limited | 781.72 Million INR | 94.222% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 98.531% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 74.183% |
| Granules India Limited | 8.6 Billion INR | 99.475% |
| Aarti Drugs Limited | 3.24 Billion INR | 98.61% |
| Bal Pharma Limited | 345.59 Million INR | 86.931% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.813% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.967% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 96.638% |
| Medicamen Biotech Limited | 245.66 Million INR | 81.615% |
| Unichem Laboratories Limited | 742.35 Million INR | 93.916% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | 60.583% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -247.53% |
| Valiant Laboratories Limited | 12.73 Million INR | -254.541% |
| Orchid Pharma Limited | 1.41 Billion INR | 96.818% |
| Medico Remedies Limited | 129.09 Million INR | 65.014% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 99.342% |
| Ipca Laboratories Limited | 13.29 Billion INR | 99.66% |
| Brooks Laboratories Limited | 41.72 Million INR | -8.237% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 89.503% |
| Piramal Enterprises Limited | -3.86 Billion INR | 101.17% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.871% |
| NATCO Pharma Limited | 18.79 Billion INR | 99.76% |
| Suven Life Sciences Limited | -992.78 Million INR | 104.549% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 154.595% |
| Strides Pharma Science Limited | 3.76 Billion INR | 98.8% |
| Indoco Remedies Limited | 2.64 Billion INR | 98.294% |
| Alpa Laboratories Limited | 229.96 Million INR | 80.36% |
| Lasa Supergenerics Limited | -65.08 Million INR | 169.399% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 101.21% |